Hypertension and stroke in Asia: A comprehensive review from HOPE Asia

the HOPE Asia Network

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


Stroke is the primary cause of disability and vascular death worldwide, including Asia. Asian characteristics that differ from the West lead to higher stroke incidence. Stroke epidemiology studies in Asia have shown varying levels of mortality, incidence, prevalence, and burden of disease. Hypertension is the most prevalent risk factor found in Asia. Besides ethnicity that is associated with stroke incidence, both systolic blood pressure, diastolic blood pressure, and blood pressure variability are positively correlated with stroke incidence. Post-stroke cognitive impairment is one of the sequelae that affect one-third of stroke survivors and has become a significant public health concern that is often neglected despite its increasing prevalence. Therefore, it is very important to prevent recurrence by treating stroke optimally and effectively. Increasing awareness and treatment adherence to hypertension, the leading risk factor for stroke, became the main goal in several countries in Asia.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalJournal of Clinical Hypertension
Issue number3
Publication statusPublished - 2021 Mar

Bibliographical note

Funding Information:
S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Hilton Pharma, Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, and Pfizer. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. Jinho J Shin has received lecture honoraria from Pfizer Inc, Hanmi Pharm. Co. Ltd., Yuhan Co. Ltd., Boryung Pharmaceutical Co. Ltd, and Menarini; consulting fees from Hanmi Pharm. Co. Ltd.; and research grants from Sanofi Pharm. and Hanmi Pharm. Co. Ltd. CH Chen has received honoraria as a member of a speaker's bureau for Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. JG Wang has received research grants from Bayer, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Sanofi, and Servier. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article .

Publisher Copyright:
© 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Hypertension and stroke in Asia: A comprehensive review from HOPE Asia'. Together they form a unique fingerprint.

Cite this